{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:32:01Z","timestamp":1788503521118,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Intramural research grants for Neurological and Psychiatric Disorders","award":["28-6"],"award-info":[{"award-number":["28-6"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Previous research indicated that nitric oxide synthase (NOS) is the key molecule for S-nitrosylation of ryanodine receptor 1 (RyR1) in DMD model mice (\n                      <jats:italic>mdx<\/jats:italic>\n                      mice) and that both neuronal NOS (nNOS) and inducible NOS (iNOS) might contribute to the reaction because nNOS is mislocalized in the cytoplasm and iNOS expression is higher in\n                      <jats:italic>mdx<\/jats:italic>\n                      mice. We investigated the effect of iNOS on RyR1 S-nitrosylation in\n                      <jats:italic>mdx<\/jats:italic>\n                      mice and whether transgenic expression of truncated dystrophin reduced iNOS expression in\n                      <jats:italic>mdx<\/jats:italic>\n                      mice or not.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Three- to 4-month-old C57BL\/6\u2009J,\n                      <jats:italic>mdx<\/jats:italic>\n                      , and transgenic\n                      <jats:italic>mdx<\/jats:italic>\n                      mice expressing exon 45\u201355-deleted human dystrophin (Tg\/\n                      <jats:italic>mdx<\/jats:italic>\n                      mice) were used. We also generated two double mutant mice,\n                      <jats:italic>mdx<\/jats:italic>\n                      iNOS KO and Tg\/\n                      <jats:italic>mdx<\/jats:italic>\n                      iNOS KO to reveal the iNOS contribution to RyR1 S-nitrosylation. nNOS and iNOS expression levels in skeletal muscle of these mice were assessed by immunohistochemistry (IHC), qRT-PCR, and Western blotting. Total NOS activity was measured by a citrulline assay. A biotin-switch method was used for detection of RyR1 S-nitrosylation. Statistical differences were assessed by one-way ANOVA with Tukey-Kramer post-hoc analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>mdx<\/jats:italic>\n                      and\n                      <jats:italic>mdx<\/jats:italic>\n                      iNOS KO mice showed the same level of RyR1 S-nitrosylation. Total NOS activity was not changed in\n                      <jats:italic>mdx<\/jats:italic>\n                      iNOS KO mice compared with\n                      <jats:italic>mdx<\/jats:italic>\n                      mice. iNOS expression was undetectable in Tg\/\n                      <jats:italic>mdx<\/jats:italic>\n                      mice expressing exon 45\u201355-deleted human dystrophin, but the level of RyR1 S-nitrosylation was the same in\n                      <jats:italic>mdx<\/jats:italic>\n                      and Tg\/\n                      <jats:italic>mdx<\/jats:italic>\n                      mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Similar levels of RyR1 S-nitrosylation and total NOS activity in\n                      <jats:italic>mdx<\/jats:italic>\n                      and\n                      <jats:italic>mdx<\/jats:italic>\n                      iNOS KO demonstrated that the proportion of iNOS in total NOS activity was low, even in\n                      <jats:italic>mdx<\/jats:italic>\n                      mice. Exon 45\u201355-deleted dystrophin reduced the expression level of iNOS, but it did not correct the RyR1 S-nitrosylation. These results indicate that iNOS was not involved in RyR1 S-nitrosylation in\n                      <jats:italic>mdx<\/jats:italic>\n                      and Tg\n                      <jats:italic>\/mdx<\/jats:italic>\n                      mice muscles.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12891-020-03501-0","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T08:04:06Z","timestamp":1595318646000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["iNOS is not responsible for RyR1\u00a0S-nitrosylation in mdx mice with truncated dystrophin"],"prefix":"10.1186","volume":"21","author":[{"given":"Ken\u2019ichiro","family":"Nogami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elhussieny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fusako","family":"Sakai-Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tanihata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Kira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Miyagoe-Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4780-6290","authenticated-orcid":false,"given":"Shin\u2019ichi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,21]]},"reference":[{"key":"3501_CR1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919\u201328.","journal-title":"Cell."},{"key":"3501_CR2","first-page":"498","volume":"45","author":"M Koenig","year":"1989","unstructured":"Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bettecken T, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet. 1989;45:498\u2013506.","journal-title":"Am J Hum Genet"},{"key":"3501_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1152\/physrev.00007.2015","volume":"96","author":"DG Allen","year":"2016","unstructured":"Allen DG, Whitehead NP, Froehner SC. Absence of dystrophin disrupts skeletal muscle signaling: roles of Ca2+, reactive oxygen species, and nitric oxide in the development of muscular dystrophy. Physiol Rev. 2016;96:253\u2013305.","journal-title":"Physiol Rev"},{"key":"3501_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nm.1916","volume":"15","author":"AM Bellinger","year":"2009","unstructured":"Bellinger AM, Reiken S, Carlson C, Mongillo M, Liu X, Rothman L, et al. Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nat Med. 2009;15:325\u201330.","journal-title":"Nat Med"},{"key":"3501_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/nrm1569","volume":"6","author":"DT Hess","year":"2005","unstructured":"Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS. Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol. 2005;6:150\u201366.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3501_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/35055104","volume":"3","author":"SR Jaffrey","year":"2001","unstructured":"Jaffrey SR, Erdjument-Bromage H, Ferris CD, Tempst P, Snyder SH. Protein S nitrosylation: a physiological signal for neuronal nitric oxide. Nat Cell Biol. 2001;3:193\u20137.","journal-title":"Nat Cell Biol"},{"key":"3501_CR7","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1093\/hmg\/dds176","volume":"21","author":"C Gentil","year":"2012","unstructured":"Gentil C, Leturcq F, Ben Yaou R, Kaplan JC, Laforet P, P\u00e9nisson-Besnier I, et al. Variable phenotype of del45-55 Becker patients correlated with nNOS\u03bc mislocalization and RyR1 hypernitrosylation. Hum Mol Genet. 2012;21:3449\u201360.","journal-title":"Hum Mol Genet"},{"key":"3501_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/path.2799","volume":"223","author":"D Li","year":"2011","unstructured":"Li D, Yue Y, Lai Y, Hakim CH, Duan D. Nitrosative stress elicited by nNOS\u03bc delocalization inhibits muscle force in dystrophin-null mice. J Pathol. 2011;223:88\u201398.","journal-title":"J Pathol"},{"key":"3501_CR9","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1172\/JCI36612","volume":"119","author":"Y Lai","year":"2009","unstructured":"Lai Y, Thomas GD, Yue Y, Yang HT, Li D, Long C, et al. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest. 2009;119:624\u201335.","journal-title":"J Clin Invest"},{"key":"3501_CR10","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1074\/jbc.274.4.2193","volume":"274","author":"S Kameya","year":"1999","unstructured":"Kameya S, Miyagoe Y, Nonaka I, Ikemoto T, Endo M, Hanaoka K, et al. Alpha1-syntrophin gene disruption results in the absence of neuronal-type nitric-oxide synthase at the sarcolemma but does not induce muscle degeneration. J Biol Chem. 1999;274:2193\u2013200.","journal-title":"J Biol Chem"},{"key":"3501_CR11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/0092-8674(95)90471-9","volume":"82","author":"JE Brenman","year":"1995","unstructured":"Brenman JE, Chao DS, Xia H, Aldape K, Bredt DS. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell. 1995;82:743\u201352.","journal-title":"Cell."},{"key":"3501_CR12","doi-asserted-by":"publisher","first-page":"9142","DOI":"10.1073\/pnas.93.17.9142","volume":"93","author":"WJ Chang","year":"1996","unstructured":"Chang WJ, Iannaccone ST, Lau KS, Masters BS, McCabe TJ, McMillan K, et al. Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. Proc Natl Acad Sci U. S A. 1996;93:9142\u20137.","journal-title":"S A"},{"key":"3501_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021618","volume":"6","author":"D Li","year":"2011","unstructured":"Li D, Shin JH, Duan D. iNOS ablation does not improve specific force of the extensor digitorum longus muscle in dystrophin-deficient mdx4cv mice. PLoS One. 2011;6:e21618.","journal-title":"PLoS One"},{"key":"3501_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bbrc.2018.09.039","volume":"505","author":"J Tanihata","year":"2018","unstructured":"Tanihata J, Nagata T, Ito N, Saito T, Nakamura A, Minamisawa S, et al. Truncated dystrophin ameliorates the dystrophic phenotype of mdx mice by reducing sarcolipin-mediated SERCA inhibition. Biochem Biophys Res Commun. 2018;505:51\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"3501_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/mus.21873","volume":"43","author":"J-H Shin","year":"2011","unstructured":"Shin J-H, Hakim C, Zhang K, Duan D. Genotyping mdx, mdx3cv and mdx4cv mice by primer competition PCR. Muscle Nerve. 2011;43:283\u20136.","journal-title":"Muscle Nerve"},{"key":"3501_CR16","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/hmg\/9.7.1033","volume":"9","author":"M Yoshida","year":"2000","unstructured":"Yoshida M, Hama H, Ishikawa-Sakurai M, Imamura M, Mizuno Y, et al. Biochemical evidence for association of dystrobrevin with the sarcoglycan-sarcospan complex as a basis for understanding sarcoglycanopathy. Hum Mol Genet. 2000;9:1033\u201340.","journal-title":"Hum Mol Genet"},{"key":"3501_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/jb\/mvv084","volume":"159","author":"M Imamura","year":"2016","unstructured":"Imamura M, Nakamura A, Mannen H, Takeda S. Characterization of WWP1 protein expression in skeletal muscle of muscular dystrophy chickens. J Biochem. 2016;159:171\u20139.","journal-title":"J Biochem"},{"key":"3501_CR18","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/jgm.1190","volume":"10","author":"J Tanihata","year":"2008","unstructured":"Tanihata J, Suzuki N, Miyagoe-Suzuki Y, Imaizumi K, Takeda S. Downstream utrophin enhancer is required for expression of utrophin in skeletal muscle. J Gene Med. 2008;10:702\u201313.","journal-title":"J Gene Med"},{"key":"3501_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ebiom.2016.08.020","volume":"11","author":"Y Mikami","year":"2016","unstructured":"Mikami Y, Kanemaru K, Okubo Y, Nakaune T, Suzuki J, Shibata K, et al. Nitric oxide-induced activation of the type 1 ryanodine receptor is critical for epileptic seizure-induced neuronal cell death. EBioMedicine. 2016;11:253\u201361.","journal-title":"EBioMedicine."},{"key":"3501_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nm.3019","volume":"19","author":"N Ito","year":"2013","unstructured":"Ito N, Ruegg UT, Kudo A, Miyagoe-Suzuki Y, Takeda S. Activation of calcium signaling through Trpv1 by nNOS and peroxynitrite as a key trigger of skeletal muscle hypertrophy. Nat Med. 2013;19:101\u20136.","journal-title":"Nat Med"},{"key":"3501_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/BF03402218","volume":"7","author":"JP Louboutin","year":"2001","unstructured":"Louboutin JP, Rouger K, Tinsley JM, Halldorson J, Wilson JM. iNOS expression in dystrophinopathies can be reduced by somatic gene transfer of dystrophin or utrophin. Mol Med. 2001;7:355\u201364.","journal-title":"Mol Med"},{"key":"3501_CR22","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1089\/hum.2016.041","volume":"27","author":"C Gentil","year":"2016","unstructured":"Gentil C, Le Guiner C, Falcone S, Hogrel JY, Peccate C, Lorain S, et al. Dystrophin threshold level necessary for normalization of neuronal nitric oxide synthase, inducible nitric oxide synthase, and ryanodine receptor-calcium release channel type 1 nitrosylation in Golden retriever muscular dystrophy dystrophinopathy. Hum Gene Ther. 2016;27:712\u201326.","journal-title":"Hum Gene Ther"},{"key":"3501_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1126\/science.1373522","volume":"256","author":"QW Xie","year":"1992","unstructured":"Xie QW, Cho HJ, Calaycay J, Mumford RA, Swiderek KM, Lee TD, et al. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science. 1992;256:225\u20138.","journal-title":"Science."},{"key":"3501_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1084\/jem.176.2.599","volume":"176","author":"HJ Cho","year":"1992","unstructured":"Cho HJ, Xie QW, Calaycay J, Mumford RA, Swiderek KM, Lee TD, et al. Calmodulin is a subunit of nitric oxide synthase from macrophages. J Exp Med. 1992;176:599\u2013604.","journal-title":"J Exp Med"},{"key":"3501_CR25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/0143-4160(92)90055-W","volume":"13","author":"HH Schmidt","year":"1992","unstructured":"Schmidt HH, Pollock JS, Nakane M, Forstermann U, Murad F. Ca2+\/calmodulin-regulated nitric oxide synthases. Cell Calcium. 1992;13:427\u201334.","journal-title":"Cell Calcium"},{"key":"3501_CR26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/humu.20428","volume":"28","author":"C B\u00e9roud","year":"2007","unstructured":"B\u00e9roud C, Tuffery-Giraud S, Matsuo M, Hamroun D, Humbertclaude V, Monnier N, et al. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum Mutat. 2007;28:196\u2013202.","journal-title":"Hum Mutat"},{"key":"3501_CR27","doi-asserted-by":"publisher","first-page":"13763","DOI":"10.1073\/pnas.1204638109","volume":"109","author":"Y Aoki","year":"2012","unstructured":"Aoki Y, Yokota T, Nagata T, Nakamura A, Tanihata J, Saito T, et al. Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci U S A. 2012;109:13763\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3501_CR28","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.stem.2016.01.021","volume":"18","author":"CS Young","year":"2016","unstructured":"Young CS, Hicks MR, Ermolova NV, Nakano H, Jan M, Younesi S, et al. A single CRISPR-cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells. Cell Stem Cell. 2016;18:533\u201340.","journal-title":"Cell Stem Cell"},{"key":"3501_CR29","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jocn.2006.12.012","volume":"15","author":"A Nakamura","year":"2008","unstructured":"Nakamura A, Yoshida K, Fukushima K, Ueda H, Urasawa N, Koyama J, et al. Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene. J Clin Neurosci. 2008;15:757\u201363.","journal-title":"J Clin Neurosci"},{"key":"3501_CR30","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/hmg\/ddn376","volume":"18","author":"SA Villalta","year":"2009","unstructured":"Villalta SA, Nguyen HX, Deng B, Gotoh T, Tidball JG. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum Mol Genet. 2009;18:482\u201396.","journal-title":"Hum Mol Genet"},{"key":"3501_CR31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0022-510X(94)00276-T","volume":"129","author":"C Pastoret","year":"1995","unstructured":"Pastoret C, Sebille A. mdx mice show progressive weakness and muscle deterioration with age. J Neurol Sci. 1995;129:97\u2013105.","journal-title":"J Neurol Sci"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-020-03501-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12891-020-03501-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-020-03501-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T19:16:44Z","timestamp":1626808604000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-020-03501-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3501"],"URL":"https:\/\/doi.org\/10.1186\/s12891-020-03501-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-16865\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-16865\/v1","asserted-by":"object"}]},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,21]]},"assertion":[{"value":"2 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Experimental Animal Care and Use Committee of the National Institute of Neuroscience of the NCNP approved all experimental protocols in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"479"}}